old article but still relevant.. glimplse of the potential of this company
PLYMOUTH MEETING, Penn. -- Beijing Med-Pharm Corporation (BJGP BJGP British Journal of General Practice .PK) and pSivida Limited (ASX ASX
See: Australian Stock Exchange :PSD (tool) PSD - Portable Scheme Debugger. ..... Click the link for more information., NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations
U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :PSDV PSDV Process Shut Down Valve (oil & gas) , Xetra:PSI) today announced that they have signed a licensing agreement for the clinical development, marketing, and distribution of pSivida's lead product, BrachySil(TM), in the People's Republic of China.
Ads by GoogleReal Mind Powers Can You Really Use This Technique To Your Desires - Quickly & Easily? www.realmindpowerskills.net/?Mind Incorporate in Canada Quick & Easy Registration from $99 Business Development Centre www.bdc-canada.com
Under the terms of the license, pSivida will manufacture BrachySil(TM) and Beijing Med-Pharm will be responsible for clinical development, securing regulatory approval, marketing, and distribution in China.
Beijing Med-Pharm is a US-based company with Chinese subsidiaries that offers an end-to-end solution to Western pharmaceutical companies that wish to sell their products into the Chinese marketplace.
In December 2004, Beijing Med-Pharm initiated the first-ever purchase by a foreign entity of a Chinese pharmaceutical distribution company when it signed an agreement to purchase a 100% equity interest in Beijing Wanwei Pharmaceutical Co., Ltd., a pharmaceutical distributor covering the bulk of Beijing's hospitals. In a historic event, this purchase was approved by the Ministry of Commerce of the People's Republic of China The Ministry of Commerce of the People's Republic of China (MOFCOM) is one of the ministries of the State Council of China.
The current minister is Bo Xilai. ..... Click the link for more information. on October 18, 2005.
BrachySil(TM) (32-P BioSilicon(TM)) will enter a Phase IIb dose-profiling study shortly as a potential new treatment for primary liver cancer (also called hepatocellular carcinoma or HCC HCC Hepatocellular Carcinoma (liver cancer) HCC Hertfordshire County Council (administrative region of south eastern England UK) HCC Harford Community College (Maryland) ). China has the highest incidence of HCC in the world, with over 345,000 estimated new cases per annum (Globocan), representing 55% of total worldwide cases. Given the clinical proof of principle already established for BrachySil(TM), focused programs are being prepared to exploit its broader utility in other significant cancer indications, including inoperable inoperable /in·op·er·a·ble/ (in-op´er-ah-b'l) not susceptible to treatment by surgery. in·op·er·a·ble adj. Unsuitable for a surgical procedure. pancreatic and secondary liver disease.
"China is the world's fastest growing market for pharmaceuticals with a large and steadily increasing incidence of the types of cancer that we believe BrachySil(TM) can effectively treat," says Gavin Rezos, Managing Director of pSivida. "Beijing Med-Pharm has an excellent model for gaining entry into this market, and we look forward to developing a market for BrachySil(TM) in partnership with them."
"BrachySil(TM) is a highly innovative product addressing a significant patient population in China," says Martyn Greenacre, Chairman of Beijing Med-Pharm. "We hope to be able to deliver this product to a large and growing market throughout China."
About Beijing Med-Pharm
Beijing Med-Pharm Corporation is a pharmaceutical marketing company that offers the following services in China through its wholly-owned subsidiary, Beijing Med-Pharm Market Calculating Co. Ltd.: pre-market entry analysis; clinical trial management; product registration; market research; and pharmaceutical marketing to physicians, hospitals and other healthcare providers.
For more information, contact Ben Austin at (917) 686-3979.
On the Web: http://www.beijingmedpharm.com
About pSivida Limited
pSivida is a global nanotechnology company committed to the biomedical sector and the development of products in healthcare. The company's focus is the development and commercialization of a modified form of silicon (porosified or nano-structured silicon) known as BioSilicon(TM).
pSivida is listed on NASDAQ (PSDV), the Australian Stock Exchange Australian Stock Exchange (ASX)
Australia's major securities market, formed when the six state stock exchanges (Adelaide, Brisbane, Hobart, Melbourne, Perth, and Sydney stock exchanges) were merged in 1987. (PSD) and in Germany on the Frankfurt Stock Exchange Frankfurt Stock Exchange
The largest of Germany's eight securities exchanges, operated by Deutsche Borse AS. on the XETRA system (German Symbol: PSI. Securities Code (WKN WKN Wertpapier-Kenn-Nummer (identifying number assigned to securities traded in Germany) WKN Warrior Knowledge Network (US Army) ) 358705). pSivida's shares also trade in the United Kingdom on the OFEX OFEX Off Exchange (Over-The-Counter Market established in 1995, Specialising in Smaller Companies) International Market Service (IMS (1) See IP Multimedia Subsystem.
(2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. ) under the ticker symbol PSD. pSivida is a founding member of the NASDAQ Health Care Index and the Merrill Lynch Nanotechnology Index.
For more information, visit www.psivida.com
In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995, including statements regarding Beijing Med-Pharm's and pSivida's performance under the contract, clinical studies and trials involving BrachySil, the development of BrachySil in the Chinese market, and the completion of the acquisition of Wanwei and Beijing Med-Pharm's expectations regarding the effect of the acquisition of Wanwei on Beijing Med-Pharm's business and its opportunities in the Chinese pharmaceutical market. Forward-looking statements provide Beijing Med-Pharm's current expectations or forecasts of future events. Beijing Med-Pharm's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and the Chinese pharmaceutical market, and due to risks and uncertainties associated with these conditions, with the ability of the parties to satisfy their obligations under the contract, with the ability to successfully complete the clinical studies and trials involving BrachySil, with the ability to develop BrachySil in the Chinese market, with completing the acquisition of Wanwei, with integrating the Wanwei business and with operating, financing and growing Beijing Med-Pharm's business. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Beijing Med-Pharm undertakes no obligation to update publicly any forward-looking statement. COPYRIGHT 2005 Business Wire No portion of this article can be reproduced without the express written permission from the copyright holder. Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.
PVA Price at posting:
$6.29 Sentiment: Buy Disclosure: Not Held
